Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study - Top-Institutions - MDSpire

Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study

By
Murat Güler
Federico Canzian
August 29, 2025
0 min

Blood Cancer Journal

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Hematology-Oncology
- Cancer Genomics
- Translational Research
#2

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Hematology-Oncology
- Cancer Genomics
- Immunotherapy
#3

Fred Hutchinson Cancer Center

Seattle, WA
Key Differentiators
- Hematology-Oncology
- Genomic Epidemiology
- Cancer Immunology
#4

University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

San Francisco, CA
Key Differentiators
- Hematology-Oncology
- Genomic Medicine
- Precision Oncology
#5

National Cancer Institute (NCI)

Bethesda, MD
Key Differentiators
- Cancer Genomics
- Epidemiology
- Translational Research

Original Source(s)

Blood Cancer Journal

Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study

by Murat Güler, Federico Canzian
August 29, 2025

Related Content

Frontiers In Medicine

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study

Frontiers In Oncology

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study

Bone Marrow Transplantation

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma